EUVIMEDEUVIMED entdecken
EditorialKommentar

Crinecerfont in a First Clinical Application of a CRH Antagonist: Further Potential Uses Are Still an Open Chapter!

George P Chrousos iD

The Journal of Clinical Endocrinology & Metabolism · 2024

DOI: 10.1210/clinem/dgad513 ↗

Kurz gefasst

Editorial in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von George P Chrousos. Beteiligte Einrichtung: University Research Institute of Maternal and Child Health and Precision Medicine and UNESCO Chair on Adolescent Health Care, National and Kapodistri…. Hauptthemen laut MEDLINE: Adrenal Hyperplasia, Congenital, Amines, Thiazoles. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 8 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

More than 30 years ago, in discussions with the late Wylie Vale and other colleagues, we raised the potential usefulness of an oral, micromolecular corticotropin-releasing hormone or factor (CRH or CRF) antagonist in a long series of disorders characterized by increased CRH secretion, with one of them being classic congenital adrenal hyperplasia (CAH). A table with the potential clinical uses of a CRH antagonist was constructed then, first published in 2002 and updated in 2006 (1, 2). These included mostly stress-related disorders characterized by increased CRH secretion, such as chronic anxiety disorder, melancholic depression, idiopathic insomnia, narcotic withdrawal, premature labor, etc. It is worth describing briefly the CRH and CRH-related peptides and their tissue receptors, going over the predicted potential utility of nonpeptidic CRH antagonists, and discussing the studies by Auchus et al and Newfield et al on the use of “crinecerfont” as an adjunct therapy respectively in adults and adolescents with classic CAH (3, 4). Importantly, crinecerfont is the first micromolecular CRH antagonist to be used successfully in the clinic in the therapy of a major human genetic disorder, the classic form of CAH (3, 4). Classic CAH affects about 30 000 people in the United States and double this number in Europe (5).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenal Hyperplasia, CongenitalAminesThiazolesHumansAdolescentReceptors, Corticotropin-Releasing HormoneCRF Receptor, Type 1

Stichwörter der Autor:innen

21-hydroxylaseACTHCAHCRHCRH receptorantalarminglucocorticoidsstresscopintildacerfonturocortin

Substanzen

crinecerfontCRF Receptor, Type 1Receptors, Corticotropin-Releasing HormoneAminesThiazoles

Autor:innen und Institutionen

  • University Research Institute of Maternal and Child Health and Precision Medicine and UNESCO Chair on Adolescent Health Care, National and Kapodistrian University of Athens, Athens 11527, Greece.

ORCID-Profile: George P Chrousos

Zitieren

APA

Chrousos, G. P. (2024). Crinecerfont in a First Clinical Application of a CRH Antagonist: Further Potential Uses Are Still an Open Chapter!. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad513

Vancouver

Chrousos GP. Crinecerfont in a First Clinical Application of a CRH Antagonist: Further Potential Uses Are Still an Open Chapter!. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgad513

BibTeX
@article{Chrousos2024,
  author = {Chrousos, George P},
  title = {Crinecerfont in a First Clinical Application of a CRH Antagonist: Further Potential Uses Are Still an Open Chapter!},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2024},
  doi = {10.1210/clinem/dgad513}
}
Kostenlos starten →